After 3 years of preclinical research. a clinical Inal of FK 506 for orthotopic liver transplantation was begun In February 1989. first as a rescue therapy for patients With intractable relection With conventional immunosuppression. then as a primary drug.
Conclusions
FK 506 is a potent and superior immunosuppressive agent for orthotopic liver transplantation.
FK 506 (tacrolimus, Prograf, Fujisawa USA, Deerfield, IL), the first new baseline immunosuppressive drug to be certified by the FDA in 1 I years, has been available in pharmacies in the United States since April 1994. After 3 years of preclinical research in Chiba,l-6 Pittsburgh,7-12 Cambridge,l3-IS and elsewhere, the drug was first used clinically in February 1989, to successfully treat patients at our center who were undergoing intractable rejection of their liver allografts despite maximum cyclosporine-based therapy. 16 A few months later, extensive trials were begun with FK 506 as the primary immunosuppressant for recipients of all of the commonly transplanted organs. 17.11 We report our experience in the 1391 consecutive adult and pediatric recipients of primary liver allografts who were treated from the outset with FK 506 between August 18, 1989 , and the end of 1993. The first 120 of these patients were reported at the American Surgical Association in 1990. 17 The subsequent case collection included an internal cohort of 79 optimum risk patients who participated in a randomized trial ofFK 506 versus cyclosporine, which has been reported elsewhere. 19 However, the current analysis is of all cases, totaling 2.6 times more than the combined number in the recently completed American and European multicenter trials, which have not been published yet. We describe the impact of this drug on our program. and mention some of the management principles that have been found to be applicable to the transplantation of other organs.
METHODS case Material
The heterogeneous indications for operation. patient ages. and patient degrees of urgency according to United Network for Organ Sharing (UNOS) criteria are summarized in Table I . Infants and children accounted for 203 recipients. in whom the most common diagnosis was biliary atresia. Almost 213 of the 1188 adults had postnecrotic cirrhosis with various etiologies.
To judge the impact of FK 506 on our program. the 1989-1993 (n = 1391)-same as the previous advance (3), but with FK. 506 instead of cyclosporine. For a more detailed comparison between the previous and current regimens, the 1212 patients in Group 3 were analyzed in the same detail as the 1391 patients in Group 4. The collective case profiles were comparable except for trends in the later period for older age candidates, a higher percentage of postnecrotic cirrhosis, and more extremely ill patients (Table 1) .
Immunopathologic and Surgical Procedures
With rare exceptions, ABO identical donors were used. Human lymphocyte antigen ma,tching was random. Because Iymphocytotoxic results became available after the fact. 10% oflivers were transplanted across positive crossmatches. 22 The panoply of variations used for the donor operations and transplant operations has been described elsewhere. 21 Needle biopsies were taken frequently to determine the cause of graft dysfunction or routinely during the early part of the study. The histopathologic criteria of rejection have been standardized thoroughly. 23 
Immunosuppression

FK505
The general policies were the same as reponed to the American Surgical Association in 1990 17 and were similar to those developed previously for cyclosporine. 21 The nephrotoxicity. neurotoxicity. and diabetogenicity of FK 506 were delineated and shown to be dose related from the OUtset.I7.II.l4 In addition. it was promptly learned that defective metabolism of the drug when there was hepatic graft dysfunction necessitated downward dose adjustments. 17 .:z,. 26 Consequently. dose revisions were guided by the balance between rejection control. toxicity. and trough plasma levels ofFK 506. which were measured with an enzyme immunoassay techniQue~7 and targeted to 1 ng/mL. For the first cases. the initial
• 8 10 intravenous doses were 0.1 5 mg/kg/day given in divided 4--hour boluses; however, in May 1990, these were reduced to 0.10 mg/kg/day and administered by continuous infusion until oral alimentation was resumed. When these doses still were found to be toxic for a significant number of patients. intravenous induction was further reduced in August 1991 to O.OS mg/kg/day. The oral doses that originally were 0.3 mg/kg/day also were scaled down commensurately.
The drift to more conservative dosing is illustrated in Figure I in subgroups of high-. medium-. and low-dose recipients who were selected for special study because they were free of confounding factors. Conditions for inclusion were preoperative serum creatinine < 1.5 mg%, preoperative fasting blood sugar < I SO mg%. and good early hepatic graft function. The results of such studies improve management policies for more complex cases. They showed that avoidance of the early postoperative FK 506 plasma spike essentially eliminated the toxicity problems that bedeviled our first patients and those subsequently entered into the early multicenter trials. Imponantly, the incidence of rejection was not increased as the FK 506 doses were diminished (Fig. I) . The penalty, however, was the need for compensatory increases in prednisone doses and a consequent statistically greater incidence of hyperglycemia (Fig. I , second panel from bottom) until these doses could be weaned. On a body weight basis. children required average FK 506 doses 1.52 times greater than those of adults to achieve equivalent plasma trough levels. In both age groups, progressive weaning to lower doses throughout the first year and subsequently of FK 506 (Fig. 2 ) and prednisone made management easier. reduced toxicity, and assured a high quality ofHfe.
Other Drugs
In the first cases. 1 g of methylprednisolone was given intravenously to adults during operation, followed by a 5-day burst of methylprednisolone, which was staned at 200 mg on the first day and reduced daily in 40 mg steps until 20 mgjday was reached on postoperative day 6. Appropriately lower doses were given to infants and children. During a second phase. treatment was begun with 20 mgjday methylprednisolone. a poticy still followed on a discretionary basis with some fragile recipients. However. the high-dose steroid burst at the beginning has been shown to be effective prophylaxis in the event of a positive Iymphocytotoxic crossmatch l l and is our current routine standard because the results of the immunologic tests usually are not available at the time of operation. With either kind of induction. prednisone doses
were weaned over several months and eventually stopped if there was no evidence of rejection.
Oinical diagnoses of rejection episodes were confirmed by needle biopsy. If they were unresponsive to increasing the maintenance doses ofFK 506, the rejections were treated with a single leg bolus of methylprednisolone or hydroconisone for adults or with smaller quantities for children. If rejection persisted, additional steroids were given, a 3-to 5-day course of 5 or 10 mg/day OKT3 was considered. and in a few cases, azathioprine was added.
The Cross-Over Phenomenon
With the first clinical use of FK 506, it was noted I6 • 29 and soon widely confirmed that the drug had a remarkable ability to halt and reverse liver rejection that was intractable, despite optimal cyciosporine-based therapy. After rescue, most of these patients were liberated from dependence on high doses of steroids. This prima Jacie evidence of superiority raised troubling ethical issues about randomized trials in such a high-risk population.
These same questions of propriety had been raised in 1980, when cyciosporine replaced azathioprine. 3O and a decade later, patient demand for FK 506 and the determination of the physicians and surgeons to give what they believed to be optimal treatment generated tumultuous conflict with the Institutional Review Board, which had mandated such a trial. As a compromise, a trial was begun, but only for low-risk patients. 19.31 In the meantime, a large scale switch was occurring from cyclosporine to FK 506. The crossover eventually totalled 437 patients in our program alone. with an estimated 1000 examples elsewhere in the United States. In 1991, an interinstitutional advisory group, impaneled by the University of Pittsburgh as a watchdog safeguard for patients' rights. recommended discontinuance of the randomized trial. and with the concurrence of the Institutional Review Board and the Food and Drug Administration (FDA), this was done. With freedom of patient choice in effect. FK 506 replaced cyclosporine (Fig. 3 ).
Data Analysis
Patient survival was calculated from the date of transplantation until patient death. and graft survival was calculated from the date of transplantation until retransplantation or patient death. Survival curves were generated using the life table method and were compared using the log rank (Mantet-Cox) test. Cox's proponionai hazards model was used to analyze different causes of monality and different causes of graft failure in the patients from Group 3. who received cyclosporine. com-pared with those of Group 4, who received FK 506. Differences in group means were tested using the oneway analysis of variance; differences in proportions were tested using Pearson's chi square test of association. A p value < 0.05 was considered statistically significant.
RESULTS
Survival
Patient survival during the 30-year history of clinical liver transplantation improved in leaps rather than steps (Fig. 4) . The greatest single increment was the advent of cyclosporine, 21.32 which was first given to a liver recipient by Calne et al. 33 A small additional gain (NS, p = 0. (8) came with the introduction of UW solution (Group 3). Further improvement relative to what had been achievable previously already was evident at the time of our presentation in 1990, at the American Surgical Association, of the first 120 liver recipients who represented our learning curve. With >4 years follow-up, 13 (86.7%) of the 15 original pediatric recipients and 81 (77.1 %) of the 105 adults remain well. All of the survivors are working, in school, or fully functional in home life. The more than tenfold expansion of this experience has confirmed the initial conclusions.
Pediatric Recipients
Infants and children of all ages, with all diagnoses. and of all urgency categories, including the high-risk UNOS 4, had an improved prognosis ( Table 2) . ---+--
TIme After Transplantation (years) 
Adult Recipients
An improvement also was observed in the adults that was significant overall (p < 0.0005), evident in all eight subgroups, and significant in four of the eight (Table 3) . However, the large survival gap in the patients with hepatitis B virus was primarily a result of avoidance ofhepatitis E antigen-positive recipients in the FK 506 era.
Graft Survival
The survival slopes in the different eras and their degree of separation from each other were parallel to those of patient survival. but approximately I ()% lower (Fig.  5) . The higher patient survival reflected the benefit of reo transplantation. The improvement of graft survival when UW solution was added to cyclosporine-based immunosuppression (Group 2 VS. Group 3) was significant (p -0.0057), as was the funher improvement with FK S06 (Group 3 VS. Group 4; p < 0.0000).
Causes of Death
The first 3 months after liver transplantation has long been known to be the period of principal mortality (Fig.  4) . During this time. the same kinds ofletha! complications were seen in the cyclosporine and FK 506 groups, but they occurred less frequently with FK S06 in aU seven of the cause of mortality categories of both pediatric and adult cohons ( Table 4 ). The three categories in which the differences were statistically significant were technical failure (most commonly hepatic artery thrombosis or bile duct complications). sepsis. and the umbrella of immunologic reason. which included rejection.
graft versus host disease. and post-transplant Iymphoproliferative disorders.
In the 4-year postoperative perspective. the same three factors were identified. By Cox regression analysis. the relative risk of fatal technical complications or sepsis in children was more than four times higher with cyciosporine (Table 5 ). For adults. immunologic reason. sepsis. and disease recurrence (most commonly malignancies or hepatitis) ranged from 1.56 to 1.9S times higher with cyciosporine than with FK 506 (Table 5) .
Incidence and Causes of Retransplantation
With FK 506. reuansplantation was required in 9.9% of the pediatric recipients treated with FK 506 compared with 22.8% in those treated with cyclosporine. The lower (Table  6 ). In the 4-year perspective. the Cox regression analysis showed the same thing (Table 7) . In adults. the retransplantation rate during the first 3 months with FK 506 compared with cyclosporine was 9.8 versus 13.7%. with technical failure and rejection accounting for most of the difference. By Cox regression analysis. the risk of retransplantation because of rejection over a 4-year follow-up was 2.4 times greater with cyclosporine than with FK 506. Retransplantation for recurrent disease had a 3.5 times greater risk with cyciosporine than with FK 506; however. this was due to the same avoidance of E antigen-positive candidates described under cause of mortality (Table 3) .
DISCUSSION
Although FK 506 and cyclosporine are chemically unrelated. each with a specific cytosolic binding site of different molecular weight. J4.1' both drugs block the immune response by preventing the transcription of early T-cell activation genes. J6 Both also are nephrotoxic. neu- rotoxic. and diabetogenic.17.IS.14 In addition. the two drugs are powerful growth factors. They are hepatotrophic because they augment hepatic regeneration. 37 • 31 and they prevent the hepatocyte atrophy and organelle injury caused by Eck's fistula. 39 . 40 However. the growth effects of gingival hyperplasia. facial brutalization. and hirsutism of cyclosporine are not caused by FK 506. and the drug is associated with a lower incidence ofhypcnension and hypercholesterolemia.I,.ls Although the preceding profiles were not identical. the similarity of effects of two such diverse agents was perplexing until their mechanisms of action were clarified with molecular studies. These revealed that cyclosporine and FK 506 are essentially inactive "prodrugs" whose cytosolic binding immunophilins (cyclophilin and FKBP t 2. respectively) also are inen in isolation. 39 However. the cyclosporine-cyclophilin and FK 506-FKBP complexes activate a common target. phosphatase calcineurin. which modifies the transduction of calcium dependent signals from the surface T-cell receptor to the nucleus. J 9-4· The immunophilins are found in all cells and are suspected by related mechanisms to panicipate in the modulation of multiple immunologic. endocrinologic. growth control. and chaperone-mediated pathways.·· ..... l ThUs. there was an explanation for the common pattern of the pleotropic effects.
Similar mechanisms notwithstanding. the clinical performance of FK 506 has been superior to cyclosporine. In our :lOOned randomized liver transplantation trial. lUI as in randomized trials conducted in multiple European and American centers. crossover from cyclosporine to FK 506 because of intractable rejection (but not vice versa) was a common event that frequently prevented death or the need for retransplantation of the patients begun on cyclosporine. With anaiyses by "intent to treat." patient and graft survival was similar on both piantation 4S also was obscured by minimizing the crossover factor. Rather than perpetuate this artifact of interpretation, we have analyzed the effect that the drug has had on the welfare of the patient population in our program. Based on our participation and observation in all previous transitions in the field, and influenced by the experience reported here, we believe that FK. 506 will supplant cyc1osporine as the principal baseline drug for transplantation of the liver and other organs. Aside from the quality of life issues favoring FK 506 that have been reported in detail elsewhere-most hinging on the ass0-ciated lower need for steroids and fewer cosmetic side effects-it has permitted a reduction in global monality, either when used up front or to rescue therapeutic failures of the previous best regimen. The dramatic way in which better immunosuppression changes the mortality and "need for retransplantation" profiles also was seen in 1980, with the advent of cyc1osporine. The three categories most affected then were the same as with the later transition from cyc1osporine to FK 506-rejection, sepsis, and technical failure.
The rubric of technical failure can mean different things to different people. The best example is hepatic anery thrombosis, which we have categorized for 30 years as "technical failure" because the surgeon's poor performance always is a theoretical possibility. However, Makowka et al .
• 46 Samuel et al.,·7 and many others have shown that this complication is associated with multiple nontechnical factors, of which incompletely controlled rejection is thOUght to be a major one. Furthermore, most mechanical complications can be indirectly attributable to or aggravated by excessive immunosuppression (particularly prednisone). Once a seam is opened in the fabric of the finished transplant product by rejection or by the drugs used to control it-whether this be in the graft vasculature, drainage system, or any other component of the operation-the deadly handmaid of sepsis in the associated triad is close by.
As FK. 506 diffuses into general use. the same practical matter will be faced as during the change from azathioprine to cyclosporine concerning the difficulty of changing from a familiar therapeutic regimen to a new one. This time around. there will be a better understanding of what is involved. The prevention of organ rejection by various immunosuppressive agents has been described increasingly in terms of the molecular site of disruption of the alloactivated T-cell response. 4U9 Recent evidence. however. suggests that the control of rejection and, ultimately, graft acceptance depend on a permissive effect of these drugs on a mutual host-graft leukocyte migration that leads in successful cases to mixed. long-term microchimerism in the recipient and the transplant.'O.51 Many of the enigmas of transplantation immunology can be explained by the recent discovery of this chimerism. The events with immunosuppression leading to the ubiquitous persistence of donor leukocytes in recipient tissues imply that there is a widespread engagement. activation. and inactivation of the immunocytes of both donor and recipient ceU populations. and ultimately. the development of various degrees of donor specific nonreactivity. Of critical importance for transplantation of leukocyte-rich organs. such as the liver and intestine. recipient-specific nonreactivity of the chimeric donor cells also must evolve if the patient is to escape the complication of graft versus host disease graft versus host disease.
This fresh insight into the fundamental mechanism of allograft acceptance as a two-way immunologic transaction makes comprehensible the characteristic cycle of recovery that was first observed in kidney recipients treated with azathioprine and prednisone':: o and soon after in recipients of livers and other kinds of organs. Rejection that typically occurred in the first few days or weeks could be reversed with adrenal conical steroids. and in successful cases. most frequently represented in the liver recipient population. immunosuppression can be reduced and occasionally, stopped.S2
With this fresh insight into mechanisms. it has become possible to understand the empirically evolved therapeutic dogma on which successful whole organ transplantation is based. The dogma calls for baseline treatment with a maintenance drug or drugs pi us trial-and-error intervention with the highly dose-maneuverable adrenal conical steroids to whatever level is required to maintain stable graft function. This dogma has been able to accommodate increasingly potent new agents with variable sites of action, of which FK 506 is merely the latest example. The ease with which FK 506 could be aSsimilated into the established strategy was illustrated by our own stan-up experience I 7 and by experience in the multicenter trials in which the 28 panicipating teams (10 in Europe and 18 in the United States) were not permitted to have a familiarizing pilot experience with the new agent. However, the requisite management skills followed a well-worn trail and were acquired so quickly that the learning curve was scarcely demonstrable in the better ::enters. Armed now with a drug as potent as FK 506, the same generic treatment formula should be applicable to further improvements in organ transplantation. If our ::ontention is valid that the migration and grafting of "passenger leukocytes" of bone marrow origin is the seminal explanation for allograft acceptance, the next steps will involve manipulation of this process. In a direct extension of the concept, 'J we currently are augmenting leukocyte traffic in unconditioned recipients of cadaver livers, kidney, hean, and lungs by the concomitant intravenous infusion of donor bone marrow cells UDder exactly the same conditions of FK 506-prednisone treatment used for the patients of the current repon. suggested to us all present that this was too toxic to be used and was about to be dropped from the investigator'S table. From that meeting Dr. Starzl went home to Pittsburgh and actually redid most of the trials that had been presented. Dr. Todo was one of the collaborators in the core group and they proved the drug to be very potent and very effective. both in the laboratory and in the clinical setting. . The drug is now poised to be launched as an FDA-approved immunosuppressant for liver transplantation in the United States. There are other trials going on in kidney transplantation as well as in hean and lung transplantation. and hopefully, with those concluded we'll see the indications for this drug expanded. Its use for autoimmune disease is a very interesting question that will remain to be elucidated.
The early pilot trials of Pittsburgh called for two large multicenter trials to be staned. one in Europe and one here in the United States. These multi-center trials were done as prospective open-label randomized trials and showed the following results: with a minimum of one-and-a-half-yearfollow-up of all the patients. the graft and patient survival are the same in the FKS06 and in the cyclosporine arms in the U.S. trial. The incidence of rejection is down significantly in the FK grouP. and It is a difficult thing to bring into balance. because one might think that there would even be a group of our patients that would prove to be refractory to FKS06 therapy bccauseoftheir previous refractory rejection. I think it is almost statistically significant now that this is not the case.
Is there some ki nd of enzyme induction that might go on that might make patients who are refractory to Cyclosporine more sensitive to FKS06 therapy and vice versa? I think this is an interesting biologicaJ question and I would like to have your comments on it.
The other question that I had was on the use of FKS06 in children who. in transplants of other organs. are quite subject to rejection. even perhaps more so than adults. yet apparently your FKS06 therapy in children is more effective than in adults.
Can you give us a reason for this?
Again I would like to congratulate Dr. Todo. one ofthe pia-neers in the use of this drug both in the experimental animal and then in the clinic, for being a major reason why it is now virtually on our pharmacy shelves. Our cardiac transplants in Cape Town are limited by the cost of the current drugs, our liver transplants are limited in the same way, and we in fact convert the kidney transplants to Imuran after 6 months, because cost is a problem. What will the cost ofFK506 be? Is it going to be a problem? Or has the company kept the cost a secret? DR. CHARLES MILLER (Mount Sinai Hospital. New York): I would like to congratulate Dr. Todo on a beautiful piece of work.
I noticed one point of real interest, that part of the improved survival was due to a decrease in recurrence of primary disease.
And one question would be, are these primary diseases autoimmune-type disease such as autoimmune hepatitis. primary biliary cirrhosis or sclerosing cholangitis. or is it in fact a decrease in recurrent infectious disease such as hepatitis C or hepatitis
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We have found that there has been a correlation between recurrent viral disease and the amount of rejection and/or immunosuppression you need to use. and I wonder if FK506 by preventing rejection has reduced those recurrent infections that are so problematic? I congratulate you again on a beautiful presentation. Regarding the first question from Dr. Klintmalm. whether FKS06 should be used for rescue therapy or for primary immunosuppression. I believe it should be both. From our ex perience. as I have shown in this paper. patients on this agent have a much greater chance of survival after liver transplantation than with any other conventional treatment. It is particularly so with pediatric recipients. Infants and children are greatly benefitted by the use of FK506 in terms of patient survival. graft survival. rejection episodes. and the need for other antirejection drug usage, especially steroids. This means that FKS06 should be used as a baseline immunosuppressive agent. In addition. as shown by us and others. many of the recipients who developed intractable rejection or side effects with conventional therapy were successfully rescued by FKS06. Thus. this agent should also be used as a rescue therapy. The potent immunosuppressive effect of FK506 is readily ascertained by the fact that intestinal transplantation in humans. which has never been satisfactory with conventional treatment, has become a practical reality with the advent of this agent.
I don't believe that any subgroup of patients should be eliminated from treatment with FKS06. since most of the side effects of FKS06 are equal to or less than conventional agents. and, I believe, liver recipients should be offered a better chance of survival after life-saving surgery.
Dr. Joshua Miller. we are not sure why pediatric patients have much better results than adult recipients. Since they can tolerate higher doses ofFKS06. the higher initial concentration of this agent in plasma may permit better control of graft rejection.
Reprding the question from Dr. Terblanche about the cost ofFK506, I hear from the Fujisawa Pharmaceutical Company that it would be similar to conventional agents. However. in a clinical setting, since this agent allows earlier discharge of the recipient after liver transplantation. a lower incidence ofrejection episodes. less frequent use of other anti-rejection agents. and fewer retransplantations and lower mortality rates, it offers better cost-performance.
Finally, in answer to the question from Dr. Charlie Miller why FK506 was associated with a lower incidence of recurrent liver disease. as described in this paper. strict selection for liver transplantation of patients who have hepatitis 8 virus related liver disease is a major reason for the reduction.
